玻璃体内注射Avastin联合睫状体光凝治疗虹膜新生血管性青光眼的疗效分析

目的 观察玻璃体内注射Avastin联合睫状体光凝对虹膜新生血管性青光眼的疗效及安全性.方法 24例(30眼)虹膜新生血管性青光眼患者分别继发于糖尿病视网膜病变(7例12眼)和视网膜中央静脉阻塞(17例18眼),给予玻璃体内注射25 g·L-1 Avastin 0.05 mL,并联合睫状体光凝治疗.术后随访6个月,观察术后眼压、视力、虹膜新生血管及并发症情况.结果 所有术眼虹膜新生血管均在注射Avastin后3 d内消退;1例1眼患者在全视网膜光凝过程中虹膜新生血管复发,再次注入Avastin,完成光凝后加行周边视网膜冷凝,虹膜新生血管消退.光凝后3 d平均眼压为(21.8±5.8)mmHg(1 kPa=7.5mm-Hg).1周为(18.4±2.3)mmHg,6个月眼压为(17.1±1.1)mmHg,与治疗前(51.2±7.3)mmHg相比,差异均有统计学意义(均为P<0.05).治疗前后视力差异无统计学意义.随访期间仅2眼视力有改善,其余视力无明显提高.随访期间未发现玻璃体出血、视网膜脱离和眼内炎、并发性白内障等并发症发生.结论 玻璃体内注射Avastin可明显消退虹膜新生血管,联合睫状体光凝控制眼压.对治疗虹膜新生血管性青光眼是一种安全有效的方法.     

玻璃体内注射Bevacizumab联合全视网膜光凝及复合式小梁切除术治疗新生血管性青光眼

目的 探讨玻璃体内注射Bevacizumab(商品名Avastin)联合全视网膜光凝及复合式小梁切除术治疗新生血管性青光眼的临床疗效.方法 收集2008年1月至2009年5月就诊于我院的新生血管性青光眼患者30例(30眼),随机分为2组.A组18例(18眼)行玻璃体内注射Bevacizumab 25 mmol·L-1联合全视网膜激光光凝及复合式小梁切除术.B组12例(12眼)行全视网膜光凝联合Ahmed青光眼阀植入术.2组术中均应用0.4 g·L-1丝裂霉素C.观察2组患者手术前后的视力、眼压及虹膜新生血管的变化.前房角镜检查前房角结构变化.结果 A组玻璃体内注射Bevacizumab 2～3 d后,所有患者的虹膜新生血管消失.4周内完成全视网膜光凝:注射2个月后,18眼眼压大于30 mmHg(1 kPa=7.5 mmHg),前房角为关闭状态;复合式小梁切除术后1周,眼压为7～12 mmHg;术后1个月,眼压为10～37 mmHg.B组4周内完成全视网膜光凝,虹膜新生血管部分消退.Ahmed青光眼阀植入术后1周,眼压为10～16 nnnHg;术后1个月,眼压为10～35 mmHg;术后6个月随访,2组患者在眼压控制、视力等方面差异均无统计学意义(均为P>0.05).手术成功率:A组(83.33%)高于B组(66.67%).A组未见虹膜新生血管复发.B组6眼虹膜新生血管复发,差异有统计学意义(P<0.05).结论 玻璃体内注射Bevacizumab 联合全视网膜光凝及复合式小梁切除术治疗新生血管性青光眼成功率高,并发症少,疗效显著.     

玻璃体切割联合超全视网膜光凝、白内障摘出术治疗新生血管性青光眼

目的探讨玻璃体切割联合超全视网膜光凝及白内障摘出治疗新生血管性青光眼的疗效。方法对我院收治的15眼新生血管性青光眼施行玻璃体切割联合超全视网膜光凝及白内障摘出术,观察术后眼压、视力、新生血管消退情况,并与文献报道的玻璃体切割联合小梁切除术后眼压结果比较。术后随访6～18个月。结果末次随访时眼压平均18mmHg(13～25mmHg,1kPa=7.5mmHg),13眼(86.7%)眼压≤21mmHg,另2眼(13.3%)眼压(22mmHg、25mmHg)稍高于正常水平,但较术前(50mmHg、65mmHg)明显下降。末次随访时11眼(73.3%)视力提高,4眼(26.7%)视力不变。所有患眼新生血管消退。与文献报道的玻璃体切割联合小梁切除术相比,二者手术前后眼压差类似,差异无统计学意义(P>0.05)。结论玻璃体切割联合超全视网膜光凝及白内障摘出术可较好地治疗新生血管性青光眼,其治疗效果与联合小梁切除术类似。     

改良小梁切除术治疗新生血管性青光眼

为观察改良小梁切除术对治疗新生血管性青光眼的疗效。对１５例（１５只眼）手术。由视网膜血管循环障碍引起９例，即时散大瞳孔进行视网膜光凝。结果观察３个月—４年４个月。１５例患者１１例眼压恢复正常，２例眼球轻度萎缩、２例眼压术后高于正常，但眼压有大幅度下降。４例视力明显进步。１２例虹膜新生血管消失。结论１５例手术均有降低眼压的作用。由视网膜血管病变引起的新生血管性青光眼９例，术后即散大瞳孔，进行视网膜光凝。     

超全视网膜光凝治疗虹膜新生血管

目的了解光凝治疗虹膜新生血管的疗效及其激光治疗时的参数。方法回顾总结15例出现虹膜新生血管接受氩离子激光超全视网膜光凝治疗患者的术后虹膜新生血管消退情况和眼底激光治疗参数。结果11眼(73.3%)完成超全视网膜光凝,术后3月虹膜新生血管完全消退,视力无显著下降。结论早期诊断和及时、充分、有效的眼底激光光凝治疗,能有效地促使虹膜新生血管消退,阻止病变进展。     

视盘新生血管型糖尿病视网膜病变的治疗

目的：观察光凝治疗视盘新生血管型糖尿病视网膜病变的疗效。方法：使用氩激光对68例86眼高盘新生血管型糖尿病视网膜病变患者行全视网膜光凝,其中5眼联合周边视网膜冷冻术,5眼联合玻璃体切除术。结果：全视网膜光凝术前术后视力无显著差异。平均激光治疗量为2700灶,全视网膜光凝术后新生血管消退率为63.9%,激光联合周边视网膜冷冻术后新生血管消退率为67.4%,激光联合玻璃体切除术后新生血管消退率为72.1%,结论：视盘新生血管型糖尿病视网膜病变较常规治疗需更大的激光量,激光联合周边视网膜冷冻或玻璃体切除术可增加疗效。     

小梁切除术术前应用康柏西普治疗新生血管性青光眼的远期疗效

目的观察小梁切除术前玻璃体内注射康柏西普联合广泛视网膜光凝治疗新生血管性青光眼（NVG）的远期疗效。方法回顾性分析2014年1月至2014年12月新生血管性青光眼30例（30眼）的资料所有患者行玻璃体内注射康柏西普,待新生血管消退后行小梁切除术联合广泛视网膜光凝术。随访30个月。观察治疗后眼压、视力、虹膜新生血管消退情况及并发症。结果27眼（90．00％）虹膜表面新生血管于玻璃体内注药后3～7d完全消退;另3眼术后3d明显减少,10d完全消退。眼压治疗前平均（41．23±8．96）mmHg,治疗后降至（15．93±2．91）mmHg（1mmHg=0．133kPa）。治疗前后眼压相比有统计学意义（P〈0．05）。眼压完全控制成功26眼（86．67％）,部分控制成功4眼（13．33％）。最佳矫正视力3眼（10．00％）提高。25眼（83．33％）视力无明显变化,2眼（6．67％）下降。玻璃体内注射康柏西普无明显并发症,小梁切除术中发生前房积血4眼（13．33％）,术后无浅前房、玻璃体积血或滤过泡漏。结论小梁切除术前玻璃体内注射康柏西普及术后广泛视网膜光凝治疗NVG是安全有效的,手术成功率高,远期控制眼压效果理想。     

小梁切除术联合全视网膜光凝治疗新生血管性青光眼

目的新生血管性青光眼是一种难以控制的青光眼。本文采用小梁切除术联合全视网膜光凝治疗新生血管性青光眼,探讨新生血管性青光眼治疗方法,取得满意疗效。方法对1998年10月-2002年1月收治新生血管性青光眼13例(13眼)采用在小梁切除术的同时根据眼底可见情况分次行全视网膜光凝术,全部患者均随访5月～2年。结果患者13例13眼术后眼压降至正常,虹膜新生血管消退,视乳头和视网膜新生血管部分或全部消退。4例视力提高,8例视力不变,1例视力下降。结论小梁切除术联合全视网膜光凝术,对于新生血管性青光眼可以有效地降低眼压,促进新生血管消退,防止再出血和眼压升高的发生。为新生血管性青光眼治疗的较好的选择方法。     

新生血管性青光眼联合治疗疗效分析

目的：观察抗血管内皮生长因子( vascular endothelial growth factor,VEGF)药物玻璃体腔内注射及全视网膜光凝( panretinal photocoagulation,PRP)后联合滤过手术治疗新生血管性青光眼的疗效。方法：对21例23眼患者中屈光介质透明者行抗 VEGF药物玻璃体腔内注射及PRP后新生血管消退后行复合式小梁切除术,屈光介质混浊患者行白内障或玻璃体切除术及全视网膜光凝联合复合式小梁切除术,随访3mo,对治疗前后眼压情况进行比较。结果：患者1例1眼视力提高显著,其余患者视力稳定或略有提高,所有患者虹膜新生血管均有不同程度消退。治疗前后眼压比较有统计学差异(P<0.01),所有患者均未出现术中术后严重并发症。结论：抗VEGF药物玻璃体腔内注射及PRP清除虹膜新生血管后联合滤过手术可以较快、较好地控制眼压,可有效治疗新生血管性青光眼。     

伴有虹膜新生血管的增殖性糖尿病视网膜病变手术治疗预后观察

目的 探讨伴有虹膜新生血管的增殖性糖尿病视网膜病变玻璃体手术治疗预后.方法 回顾性总结2002～2006年因增殖性糖尿病视网膜病变接受玻璃体手术治疗的住院病例,选择其中随访1月以上的病例入选,对术前伴有虹膜新生血管(INV)的患者记录其临床病程、糖尿病分型、年龄、性别、术前与术后视力、晶体状况、手术方式、PRP情况、以及治疗前后眼压和INV变化情况等并进行总结.结果 其中随访1月以上的病例242例288只眼,最长随访时间60个月.患者年龄(20～76)岁,平均年龄(53.5±10.4)岁.在入选的242例患者288只眼中,有8例8只眼术前发现INV,其中4只眼发展为新生血管性青光眼(NVG).在玻璃体手术联合眼内光凝术后,INV均有不同程度减退,大多发生在术后2周内.其中7例INV消失,1例随访期内未见INV消失.在随访期间,4例NVG患者眼压均药物控制(<21 mmHg).随访期间,5例患者术后视力较术前提高,2例视力不变,1例视力下降,所有病例术后视力均在0.02以上.结论 及时的玻璃体手术联合眼内光凝有可能促进糖尿病性INV的消退,并使NVG的眼压得以控制.     

Vitrectomy and subsequent photocoagulation in proliferative diabetic retinopathy with vitreous hemorrhage

Forty eyes in 39 patients with proliferative diabetic retinopathy, vitreal hemorrhage and progressive neovascularization in at least 3 fundus quadrants were treated with panretinal xenon photocoagulation immediately after pars plana vitrectomy. Lens extraction was performed on 7 eyes and 2 eyes were aphakic. Six months after treatment, 68% of the eyes showed an improvement in vision, 25% had vitreal rebleeding and 11% developed rubeosis iridis. While treatment had no effect on peripheral rubeosis iridis in 5 eyes, all 7 eyes with pupillary rubeosis iridis showed complete regression. The results indicate the clinical value of combining, pars plana vitrectomy with panretinal xenon photocoagulation in selected patients.     

小梁切除术联合视网膜光凝术治疗新生血管性青光眼

目的 探讨复合小梁切除术联合视网膜光凝术治疗新生血管性青光眼的疗效.方法 回顾性分析视网膜中央静脉阻塞继发新生血管性青光眼患者9例,行复合小梁切除术,术后1周予全视网膜光凝术.记录术前及术后3个月、12个月患者视力、眼压、虹膜及房角新生血管检查,眼底视网膜新生血管消退及无灌注区情况.结果 术后12个月患者视力提高8眼,1眼无明显提高.术后眼压：5例患者眼压控制在21mmHg以下;4例眼压控制欠佳,需要局部使用降眼压药物,其中2例使用一种局部降眼压药物后眼压控制在21mmHg以下,另外2例眼压不能控制.虹膜及房角新生血管消退.眼底3个月和12个月后行荧光血管造影显示新生血管消退,无水肿,毛细血管无灌注区消失.结论 复合小梁切除术联合全视网膜光凝术是一种治疗视网膜中央静脉阻塞继发的新生血管性青光眼的有效的方法.     

前部视网膜冷凝联合玻璃体切除术治疗中早期NVG

摘要目的:探讨前部视网膜冷凝联合玻璃体切除术治疗中早期新生血管青光眼(neovascular glaucoma,NVG)的临床效果。方法:采用前部视网膜冷凝联合玻璃体切除术治疗中早期新生血管青光眼31例31眼,术中全视网膜光凝。结果:患者31眼,术前眼压41.1±6.2mmHg,术后观察3~25(平均9.8)mo,眼压22.6±6.9mmHg,术前术后眼压差别具有统计学意义(P=0.002);25例眼压控制正常,眼压19.8±2.4mmHg,6例眼压34±8.2mmHg,其中3例局部药物治疗眼压控制正常,2例行二次手术,玻璃体腔青光眼阀植入术后,眼压控制满意,1例无效,患眼无光感,疼痛,行眼内容摘除术。20眼视力有不同程度的提高,5例视力不变,5例视力下降,1例无光感。30例虹膜面新生血管绝大部分或完全消退,角膜透明,前房无积血,所有病例眼部疼痛消失或明显缓解。结论:前部视网膜冷凝联合玻璃体切除术可消退虹膜面的新生血管,有利于术后眼压的控制,恢复部分视力,为中早期新生血管性青光眼提供了一个行之有效的治疗方案。     

Photocoagulation in Eales' disease

Between 1970 and 1991 the authors examined 466 cases with Eales' disease. 359 eyes of 295 of these 466 cases received photocoagulation treatment. The mean age was 30.4, ranging between 14 and 55 years. Ten eyes with persistent vitreous hemorrhage underwent pars plana vitrectomy before photocoagulation. 210 eyes were treated with xenon arc, 135 with argon laser, 12 with krypton laser and two with yellow dye laser. Hypoxic areas and retinal neovascularizations were closed completely in 298 eyes. In 21 eyes with elevated neovascularizations intruding into the vitreous cavity feeder vessel photocoagulation was used. 24 eyes with disc neovascularization were treated with panretinal photocoagulation. 12 eyes with branch vein occlusion and four eyes with central vein occlusion received photocoagulation treatment to areas of non-perfusion and retinal neovascularization. At a mean follow-up of 43 months, seven new retinal neovascularizations and three new disc neovascularizations developed in eyes which previously had received photocoagulation for retinal neovascularization and hypoxia. Nine out of 21 eyes with elevated neovascularizations developed vitreous hemorrhage. Disc neovascularization resolved completely in 13 out of 24 eyes, it partially regressed in eight eyes and did not respond to treatment in three eyes. The visual acuities were improved in 12.3%, maintained in 77.4% and deteriorated in 10.3% of the eyes after treatment. Periodic follow-up and early photocoagulation treatment is useful in stabilizing the retinal lesions and in maintaining functional levels of vision in Eales' disease.     

Combined scleral buckle and vitrectomy as a primary surgery for pseudophakic and aphakic retinal detachments

AIM: To determine whether a combined scleral buckle and pars plana vitrectomy, as a primary surgery, owns any advantage over a single scleral buckling in pseudophakic and aphakic retinal detachments. · METHODS: Thirty consecutive pseudophakic/aphakic retinal detachments were included in this retrospective study. Each patient underwent combined scleral buckle and pars plana vitrectomy, and was followed up for 3 to 14 months. Patients were examined with respect to anatomic reattachment, visual acuity improvement, and surgical complications. · RESULTS: All eyes were anatomically reattached after the first operation. All patients had an increase in their visual acuity, and there were no complications attributable to the vitrectomy procedure. · CONCLUSION: A combined surgery for primary pseudophakic/ aphakic retinal detachments offers significant benefits to scleral buckling alone. The improved success rate is contributing to the function of vitrectomy, which improves peripheral visibility and reduces the occurrence of proliferative vitreoretinopathy (PVR).     

巩膜外硅压联合玻璃体切割术治疗人工晶状体或无晶状体眼视网膜脱离

目的:探讨在治疗人工晶状体或无晶状体眼视网膜脱离中巩膜硅压联合玻璃体切割术比单纯巩膜硅压手术的优越性。方法:回顾性分析30例我院联合手术治疗的人工晶状体或无晶状体眼视网膜脱离患者的临床资料。各位患者均采用巩膜外硅压联合玻璃体切割手术修复脱离的视网膜,术后随诊3～14mo,对手术后的解剖复位、视力提高情况以及并发症进行考察。结果:所有患者(30眼)均1次手术复位成功并有不同程度的视力提高,没有发现任何玻璃体切割手术的并发症。结论:在治疗人工晶状体或无晶状体眼视网膜脱离中,巩膜外硅压联合玻璃体切割术比单纯巩膜硅压手术有明显的优越性,其成功率的提高与玻璃体切割术提高周边视网膜的可见度,以及减少PVR的发生相关。     

Endophotocoagulation

A system was developed for transvitreal application of photocoagulation using a fiberoptic probe attached to a portable xenon arc coagulator (endophotocoagulation, EPC). The system is activated by a footswitch, and the probe tip is positioned near the retina after performing a pars plana vitrectomy. This technique can be used to treat posterior retinal breaks, stop retinal bleeding, coagulate retinal neovascularization, apply scatter retinal photocoagulation in certain diabetic eyes, treat some of the ciliary processes in eyes with neovascular glaucoma, and enlarge the pupil in eyes with iris neovascularization and miosis. Endophotocoagulation was used in 169 eyes for one or more of these indications and found to be safe and reliable.     

Photocoagulation in Eales' disease

Between 1970 and 1991 the authors examined 466 cases with Eales' disease. 359 eyes of 295 of these 466 cases received photocoagulation treatment. The mean age was 30.4, ranging between 14 and 55 years. Ten eyes with persistent vitreous hemorrhage underwent pars plana vitrectomy before photocoagulation. 210 eyes were treated with xenon arc, 135 with argon laser, 12 with krypton laser and two with yellow dye laser. Hypoxic areas and retinal neovascularizations were closed completely in 298 eyes. In 21 eyes with elevated neovascularizations intruding into the vitreous cavity feeder vessel photocoagulation was used. 24 eyes with disc neovascularization were treated with panretinal photocoagulation. 12 eyes with branch vein occlusion and four eyes with central vein occlusion received photocoagulation treatment to areas of non-perfusion and retinal neovascularization. At a mean follow-up of 43 months, seven new retinal neovascularizations and three new disc neovascularizations developed in eyes which previously had received photocoagulation for retinal neovascularization and hypoxia. Nine out of 21 eyes with elevated neovascularizations developed vitreous hemorrhage. Disc neovascularization resolved completely in 13 out of 24 eyes, it partially regressed in eight eyes and did not respond to treatment in three eyes. The visual acuities were improved in 12.3%, maintained in 77.4% and deteriorated in 10.3% of the eyes after treatment. Periodic follow-up and early photocoagulation treatment is useful in stabilizing the retinal lesions and in maintaining functional levels of vision in Eales' disease.     

雷珠单抗联合多重手术与睫状体光凝术治疗新生血管性青光眼的疗效比较

目的　比较雷珠单抗联合超声乳化白内障吸出术、玻璃体切割术、全视网膜激光光凝术、镜下睫状体光凝术与单纯经巩膜外睫状体光凝术治疗新生血管性青光眼(neovascular glaucoma,NVG)的临床疗效。方法　回顾性分析2016年12月至2018年12月在武汉大学人民医院眼科中心就诊的35例（35眼）NVG患者资料。将所有患者按手术方式不同分为试验组和对照组,试验组15例,对照组20例。试验组行雷珠单抗玻璃体内注射联合超声乳化白内障吸出术、玻璃体切割术、全视网膜激光光凝术、镜下睫状体光凝术,对照组行巩膜外睫状体光凝术,比较术后1周、1个月、3个月两组治疗后的眼压、视力、虹膜新生血管及并发症等情况。结果　两组患者术前基线资料比较差异均无统计学意义（均为P>0.05）。所有患者术后1周、1个月、3个月眼压均明显下降,两组患者手术前后眼压比较差异均有统计学意义（均为P<0.05）。术后1周对照组患者眼压高于试验组,差异有统计学意义（P<0.05）,术后1个月、3个月两组差异均无统计学意义（P=0.923、0.738）。试验组视力改善率60.0%,对照组视力改善率10.0%,两组术后视力比较差异有统计学意义（P<0.05）。试验组虹膜新生血管消失率33.3%,对照组虹膜新生血管消失率10.0%,两组患者术后3个月虹膜新生血管情况比较,差异有统计学意义（P<0.05）。两组患者并发症复发率、眼球萎缩率差异均有统计学意义（均为P<0.05）。结论　雷珠单抗联合超声乳化白内障吸出术、玻璃体切割术、全视网膜激光光凝术、镜下睫状体光凝术与单纯巩膜外睫状体光凝术相比,可有效减少虹膜新生血管的形成,保存部分视力,降低低眼压及眼球萎缩等并发症风险。     

改良超全视网膜光凝术治疗高危增殖性糖尿病视网膜病变

目的：观察应用改良的超全视网膜光凝术(extra panretinal photocoagulation,E-PRP)治疗高危增殖性糖尿病视网膜病变(high risk proliferative diabetic retinopathy,hsPDR)的疗效及安全性。
　　方法：将我院2011-02/2014-12通过荧光素眼底血管造影(fundus fluorescein angiography,FFA)确定为高危 PDR患者88例102眼纳入研究。采用倍频532激光对其中52眼行改良的 E-PRP 治疗,50眼行标准全视网膜光凝术(panretinal photocoagulation, PRP)治疗。激光治疗后每3mo 行 FFA 及彩色眼底照像,对新生血管未消退、大片无灌注区未消失的患者追加光凝,随访6~36mo。
　　结果：高危 PDR 经改良的 E-PRP 和 PRP 治疗后,两组患者视力比较差异无统计学意义( P>0.05)。经改良的E-PRP 治疗后视网膜无灌注区消失、新生血管消退35眼(67%),有效率88%;有6眼因严重玻璃体积血、纤维增殖及牵拉性视网膜脱离需行玻璃体切除手术治疗,占12%。经 PRP 治疗后视网膜无灌注区消失、新生血管消退23眼(46%),有效率66%。有17眼出现视网膜前出血或玻璃体积血,需行玻璃体切除手术治疗,占34%。两组比较,新生血管消退率及有效率差异有统计学意义(P<0.05)。
　　结论：改良的 E-PRP 是治疗高危 PDR 的安全、有效手段,其疗效优于传统 PRP。